Low Float Nasdaq Breakout Idea (BSGM) Is A MedTech Company And Potential Squeeze Candidate (Details Now)

StockWireNews

Low Float Nasdaq Breakout Idea (BSGM) Is A MedTech Company And Potential Squeeze Candidate (Details Now)

$13.00 Laidlaw & Company Price Target

June 30th

Good Morning,

According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death globally.

In fact, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths.

Of these deaths, 85% were due to heart attack and stroke.

Cardiovascular devices are medical devices designed for monitoring, preventing, diagnosing, and treating diseases associated with the cardiovascular system or heart related diseases.

The market for these devices was valued at $40.8Bn in 2018 and it is projected to reach $71.1Bn in 2027; it is expected to grow at a CAGR of 6.5% from 2019 to 2027.

And, one company's game-changing first product could impact this market greatly as it aims to provide physicians with a better idea of heart related issues.

That's why for Wednesday, June 30th there is only one Nasdaq profile to have on your radar:

*BioSig Technologies, Inc. (BSGM)*

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.

The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Here’s Why PURE EP Could Be a Game-Changer

According to XTalks, PURE EP could fill a significant need because:

“The electrograms used today can be riddled with noise and artifacts coming from other equipment found in the operating room. Such a procedure can take up to six hours, potentially yielding what is referred to in the industry as a ‘dirty signal’ that’s indiscernible to interpret by many electrophysiologists.” (1)

BioSig's PURE EP was developed to address unmet needs in a large and growing market and deliver technology to improve catheter ablation treatments for arrhythmias, Atrial Fibrillation, and Ventricular Tachycardia.

“The system is intended to acquire, digitize, amplify, filter, measure and calculate, display, record and store electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data,” as further reported XTalks. (1)

Furthermore, BioSig Technologies' PURE EP system has: (2)

A signal processing platform designed to reveal the full range of cardiac signals and provide electrophysiologists with signal clarity during procedures.

The ability to refine signal clarity by reducing signal noise with higher precision.

The potential to allow surgeons to work far more accurately, decreasing the probability of a repeat procedure and increasing procedure safety.

Even more impressive, the PURE EP Systems are already installed at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic’s Florida campus, Massachusetts General Hospital, the University of Pennsylvania, and Deborah Heart and Lung Center. (3)

-----

No. 1 Potential Immediate Term Catalyst - Company's Tech To Be Featured At Stanford Retreat

BioSig’s Signal Processing Technology for Electrophysiology To Be Featured During 2021 Stanford Biodesign New Arrhythmia Technologies Retreat

Westport, CT, June 28, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company would be presenting during 2021 Stanford Biodesign New Arrhythmia Technologies Retreat, due to take place virtually on July 27, 2021. The Company will present at 2 pm PT.

[...]

“We look forward to presenting a selection of impactful clinical examples that demonstrate the applications of our latest software tools during this year’s Stanford Biodesign Retreat. We would like to thank Dr. Wang and the faculty for the outstanding agenda that highlights innovation in this crucial area of arrhythmia care,” added Olivier Chaudoir, Senior Director of Marketing of BioSig Technologies, Inc.

Read the full article here.

-----

No. 2 Potential Immediate Term Catalyst - Potential Squeeze On Horizon?

Check out BSGM's 6-month chart below:

As you can see, BSGM dropped to a $2.80 low back in May and has slowly been gaining momentum in recent weeks.

Now trading over $4.00 as of close on Tuesday, BSGM is entering an interesting area on its chart. Let me break it down.

At this moment (closing bell on 6/29), BSGM is trading above 2 key lines of potential support in its:

13-Day Exponential Moving Average (EMA)
50-Day Simple Moving Average (SMA)

With a 200-Day SMA that is being reported by Barchart as $4.41 at close on Tuesday, BSGM could be entering squeeze territory.

If potential resistance breaks down at that level today or in the near future, BSGM could start drawing a ton of interest as a profile trading above 3 key lines (13-Day EMA, 50-Day SMA, 200-Day SMA).

This is why you need to pay attention to this tidbit of info...

No. 3 Potential Immediate Term Catalyst - Low Float

According to Yahoo Finance, BSGM has a small float.

The website reports this profile to have 27.69Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, potential catalysts can send shares heading vertical in the short-term.

-----

No. 4 Potential Immediate Term Catalyst - Strong Analyst Coverage, Big Target

Last year, Laidlaw & Company provided BSGM with a $13.00 target.

From Tuesday's close, this gives BSMG over 200% potential upside.

Here's the major highlight from the report:

Major value driver, the PURE EP system is a first-to-market and novel signal processing system that could help to improve the efficacy of catheter ablation in arrhythmia patients. The key value proposition of the PURE EP system is to provide electrophysiologists with visualized original and less distorted cardiac signals after the removal of most of the noise and artifacts. This enables them more precisely to identify and destroy the diseased sites during the catheter ablation procedure and improve the success rate in treating atrial fibrillation (AFib) and ventricular tachycardia (VT). The use of the PURE EP system could potentially lead to more procedures being performed and translate to more hospital revenue. The PURE EP system was approved [510(k) clearance] in 3Q18. BSGM is conducting a randomized and blinded post-marketing clinical study to potentially demonstrate an improved signal by the PURE EP system vs. the current SOC recording/mapping system. A portion (n=34) of the outcome would be submitted for a publication, likely in 2020. With potential competitors far behind, the PURE EP system is likely to be the leading player in this space

-----

No. 5 Potential Immediate Term Catalyst - 2 Key MedTech Sales Executives Join The Team

BioSig Expands Commercial Team in Two Strategic Regions

Westport, CT, April 15, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it added two experienced electrophysiology Regional Directors to lead commercial expansion across Southeast and Central regions.

[...]

Read the full article here.

-----

Nasdaq (BSGM) Recap: Potential Immediate Term Catalysts To Know Right Now

#1. Company's Tech To Be Featured At Stanford Retreat

#2. Potential Squeeze On Horizon?

#3. Low Float

#4. Strong Analyst Coverage, Big Target

#5. 2 Key MedTech Sales Executives Join The Team

-----

Coverage is officially initiated on BSGM. When you have time later, do this:

If there are any updates today, I'll get them out to you quickly.

Sincerely,

Kai Parker

StockWireNews

Source 1
Source 2
Source 3

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading Stock Wire News email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 2/19/20 to publicly disseminate information about (BSGM) via Website, Email and SMS. We have been paid twenty-five thousand USD via bank wire transfer. We own zero shares of (BSGM). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been paid an additional five thousand USD via bank wire transfer on 2/21/20 for continuing coverage of (BSGM). We own zero shares of (BSGM). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 4/9/20 to publicly disseminate information about (BSGM) via Website, Email and SMS. We have been paid seven thousand USD via bank wire transfer. We own zero shares of (BSGM). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 6/17/20 to publicly disseminate information about (BSGM) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (BSGM). Pursuant to an agreement between StockNewsWire, LLC and Legends Media, LLC, StockWireNews has been hired for a one day period on 1/13/21 to publicly disseminate information about (BSGM) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (BSGM). Pursuant to an agreement between StockNewsWire, LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 6/30/21 and ending on 7/1/21 to publicly disseminate information about (BSGM) via Website, Email and SMS. We have been paid twenty-six thousand five hundred USD via bank wire transfer. We own zero shares of (BSGM). To date, we have been compensated a total of one hundred and eighteen thousand five hundred USD to disseminate information about (BSGM).